A WORLD LEADER IN RIBOSOME TARGETED GENETIC THERAPIES

A WORLD LEADER IN
RIBOSOME TARGETED
GENETIC THERAPIES

Who We Are

Leadership

Sumit Aggarwal
Sumit Aggarwal
President and Chief Executive Officer
Mr. Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1, 2021, and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early stage technology company to a rare disease and oncology-focused organization. ...see morePrior to joining Zikani, from 2015 to 2018, Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018, Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice.

Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by reinvigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.

...see less
Vijay Modur
Vijay Modur
Head of Research and Development
Dr. Vijay Modur became our Head of Research and Development on April 1, 2021, and previously served as the Head of R&D, Chief Scientific and Medical Officer of Zikani Therapeutics, Inc. In his more than 20 years in pharmaceutical and diagnostic roles in R&D, Dr. Modur has successfully translated research discovery efforts into products that impacted medical practice. ...see morePrior to joining Zikani, Dr. Modur led the venglustat rare disease program at Sanofi across multiple rare disease indications into phase 2 and phase 3 clinical development as well as other early development programs. Prior to Sanofi, Dr. Modur held leadership roles at HTG Molecular, Novartis Oncology and Merck Research Labs. Dr. Modur obtained his M.B.B.S. from Karnatak University and his Ph.D. from University of Utah. Dr. Modur was a resident in Clinical Pathology at Washington University School of Medicine where he also completed his post-doctoral fellowship.

...see less
Daniel Geffken
Daniel Geffken
Interim Chief Financial Officer
Mr. Daniel Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. Mr. Geffken is a founder of Danforth Advisors and brings more than 30 years of financial experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with over a billion dollars in market capitalization. ...see moreHe has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, Mr. Geffken has participated in eleven initial public offerings. Over the course of his career, he has helped life sciences companies raise more than two billion dollars in equity and debt securities. Mr. Geffken holds a B.S. from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.

...see less
Ali Hariri
Ali Hariri
Chief Medical Officer
Ali Hariri, M.D., is Eloxx’s Chief Medical Officer, responsible for overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases. Prior to joining Eloxx, Dr. Hariri served as Senior Global Project Head in Rare Disease Clinical Development at Sanofi-Genzyme where he oversaw key functions responsible for advancing a number of investigational therapies along with approval of supplemental indications for on-market therapies....see more

Prior to his role as Global Project Head at Sanofi-Genzyme, Dr. Hariri held several positions of increasing responsibility with expertise across a range of therapeutic areas including renal and immunology. Before joining Sanofi, Dr. Hariri held clinical development and medical affairs roles at Ionis and Takeda coordinating publication planning and health economics research. Dr. Hariri was also a practicing nephrologist.

Dr. Hariri earned his M.D. from the University of California San Diego School of Medicine, and his Bachelor of Science degree in biochemistry from California State University. He completed his residency at Case Western Reserve and a fellowship at Yale University School of Medicine. He served as faculty in the section of nephrology at Yale.

...see less

Board of Directors

  • Tomer Kariv
    Chairman

    Mr. Tomer Kariv, M.D is Chairman of our Board and has served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established six funds with over $700 million under management and invested in over 65 portfolio companies....see more Mr. Kariv also serves on the board of directors of many of The Pontifax Group’s portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd., VBI Vaccines Inc., LogicBio, and 89Bio Ltd. He previously served as a Director of Medical Compression Systems Ltd., Insuline Medical Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Arno Therapeutics, Stimatix Ltd., Applied Immune Technologies, Allium Ltd., Tucos, Inc., Therapix Biosciences Ltd., Otic Pharma Ltd., Observer in Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., and CollPlant Holdings Ltd. Mr. Kariv has 14 years of experience as a seasoned venture capital industry executive and has played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv received a Bachelor of Arts degree in economics from Harvard University and a Juris Doctor from Harvard Law School.

    ...see less

  • Jasbir Seehra, PhD
    Director

    Dr. Jasbir Seehra has served as a member of our Board since February 2018. Dr. Seehra is Chief Executive Officer of Keros Therapeutics, a position he has held since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel, where he currently serves on their Scientific Advisory Board. Dr. Seehra was part of a team of scientific advisors for many companies....see more He has served as an advisor on Ember’s Scientific Advisory Board since the company’s launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute’s small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening, and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received both his Bachelor of Science and Ph.D. in Biochemistry from the University of Southampton, England, and completed his postdoctoral work at the Massachusetts Institute of Technology.

    ...see less

  • Ran Nussbaum
    Director

    Mr. Ran Nussbaum has served as a member of our Board since 2013. Mr. Nussbaum is managing partner and co-founder of Pontifax. The fund runs more than 60 portfolio companies around the globe. Mr. Nussbaum’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight....see more He previously served as a board member for several companies, including Kite Pharmaceuticals (sold to Gilead), cCAM Therapeutics (sold to Merck), ArQule (sold to Merck) and Prevail Therapeutics (sold to Eli Lilly). Currently, Mr. Nussbaum sits on the Board of Directors of many of Pontifax’s portfolio companies including UroGen (URGN), Kamari and Lutris. Mr. Nussbaum also serves as Chairman of the Board for both Keros (KROS) and Kamari.

    ...see less

  • Sumit Aggarwal
    President and CEO

    Mr. Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1, 2021, and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early stage technology company to a rare disease and oncology-focused organization....see more Prior to joining Zikani, from 2015 to 2018, Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018, Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice.

    Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by reinvigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.

    ...see less

  • Rajesh Parekh, PhD
    Director

    Dr. Rajesh Parekh joined our Board on April 1, 2021, and previously served as a director of Zikani Therapeutics, Inc. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. ...see moreHe has founded or served on the boards of several life sciences companies in the United States and Europe including Avila Therapeutics, Inc.; EUSA Pharma (Europe) Limited; Biocartis NV; Amsterdam Molecular Therapeutics (AMT) Holding NV (now uniQure); Aura, Inc.; Itara Ltd., Cellnovo SA; Artax, Inc.; and Project Paradise Limited. He was also a member of the Supervisory Board of the Novartis Venture Fund and is currently Chairman of the Board of Directors of Galapagos NV. Dr. Parekh also currently serves as a member of the board of directors of Advent Venture Partners LLP, Advent Life Sciences LLP, Aleta, Inc., Alpha Anomeric SA, Amphista Therapeutics Ltd., Arrakis, Inc., Aura Biosciences, Capella BioSciences Ltd., Levicept Limited, PE Limited, Pheno Therapeutics Ltd., and Tridek-One Therapeutics SAS. Mr. Parekh received his Master of Arts degree in biochemistry and Doctor of Philosophy in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor.

    ...see less

  • Gadi Veinrib
    Director

    Mr. Gadi Veinrib has served as a member of our Board since 2014. Mr. Veinrib serves as the Chairman of the Board of Aqua Maof Aquaculture Technologies Ltd., a world leader in indoor aquaculture technology, as well as other companies in the Aqua Maof Global Aquaculture Group. Mr. Veinrib serves as a board member in Israeli based Meteo-Logic Ltd. and Minute Ltd. Mr. Veinrib served as Vice President of Elron Electronic Industries Ltd.,...see moreas well as a director of companies within Discount Investment Corporation Ltd. (a member of the IDB Group), including Netvision Ltd., RDSeed Ltd., Cloudyn Software Ltd., and Nana10 Ltd. Mr. Veinrib holds a Bachelor of Arts in economics from Tel Aviv University.

    ...see less

  • Dr. Zafrira Avnur, Ph.D
    Director

    Dr. Zafrira Avnur, Ph.D. has served as a member of our Board since December 2017. Dr. Avnur is the Chief Scientific Officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering, from 2009 until October 2016. Dr. Avnur was also named Global Head of Neglected Diseases, Roche Partnering, from 2010 until 2012....see more She is responsible for the creation of nine startup companies and serves on the board of directors of several portfolio companies. Prior to her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as a Liaison between Pharma and Diagnostic Divisions and contributed to the PHC (Personalized Health Care) initiative. Dr. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years, holding a number of positions progressing from scientist and manager to one with global responsibilities overseeing the advancement of compounds from the bench into the clinic. She was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. Dr. Avnur received both her Bachelor of Science and Master of Science degrees in biology from Ben Gurion University and earned a Ph.D. in Immunology from the Weizmann Institute of Science. Dr. Avnur also conducted post-doctoral work at Stanford Medical Center in the Cancer Immunology Department.

    ...see less

  • Steven D. Rubin
    Director

    Mr. Steven Rubin has served as a member of our Board since December 2017, and previously served as a member of the Sevion Therapeutics, Inc. Board of Directors since May 2014. Mr. Rubin is the Executive Vice President, Administration, and a Director of OPKO Health, Inc. Mr. Rubin currently serves as a Director of VBI Vaccines, Inc., Red Violet, Inc.; Kidville, Inc.; Non-Invasive Monitoring Systems, Inc.; Cocrystal Pharma, Inc.; Castle Brands, Inc.; Neovasc, Inc.; and ChromaDex Corp....see more Mr. Rubin previously served as a Director of Cogint, Inc. prior to the spinoff of Red Violet from Cogint in March 2018; Dreams, Inc.; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.; SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc.; Tiger X Medical, Inc. prior to its merger with BioCardia, Inc.; and PROLOR Biotech, Inc. prior to its acquisition by OPKO Health, Inc. Mr. Rubin received a Bachelor of Arts in Economics from Tulane University and a Juris Doctor from the University of Florida.

    ...see less

  • Alan Walts, PhD
    Director

    Dr. Alan Walts joined our Board on April 1, 2021, and previously served as Executive Chairman of Zikani since May 2020. Dr. Walts is a U.S.-based Venture Partner with Advent Life Sciences, a position he has held since January 2014. Dr. Walts has served as Executive Chairman and Director of PIC Therapeutics since 2016 and Artax Biopharma since 2017. Dr. Walts is also a founder, director and treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019....see more He serves as an independent Director of Neuroelectrics Corp, and a business advisor and board observer of several private companies including Amylyx Pharmaceuticals, Arrakis Therapeutics, Alpha Anomeric and Amphista Therapeutics. Dr. Walts’ previous board experience includes X4 Pharmaceuticals, Aura Biosciences, and Arrakis Therapeutics. Dr. Walts has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013, Dr. Walts most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Dr. Walts received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.

    ...see less

Key Collaborators

Key Advisors